First case report of perioperative immunochemotherapy with envafolimab in pulmonary large-cell neuroendocrine carcinoma

Pulmonary large-cell neuroendocrine carcinoma (PLCNEC) is a rare and highly aggressive cancer with no standardized perioperative treatment. This study aimed to explore the efficacy and safety of perioperative immunochemotherapy with envafolimab for resectable PLCNEC. We report a 67-year-old male patient with stage IIIA PLCNEC (cT4N0M0) who received four cycles of neoadjuvant immunochemotherapy (envafolimab + carboplatin + etoposide), followed by radical surgery and adjuvant therapy. After neoadjuvant treatment, the tumor shrank by 48.1% and achieved partial response. The patient underwent successful R0 resection and achieved major pathological response. As of May 2025, the patient remained disease-free for 29 months postoperatively, with no grade greater than or equal to 3 adverse events. Notably, clinical benefit was achieved despite negative programmed death-ligand 1 (PD-L1) expression. Perioperative immunochemotherapy with envafolimab is a promising therapeutic option for patients with resectable PLCNEC, even in those with negative PD-L1 expression.

Authors

Institutions

Publication Details

Journal
Anti-Cancer Drugs
Published
2026-11-18
DOI
https://doi.org/10.1097/cad.0000000000001851
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

First case report of perioperative immunochemotherapy with envafolimab in pulmonary large-cell neuroendocrine carcinoma

Huidong Long, Yunen Lin, Jin-Yu Zhou
Anti-Cancer Drugs
Lung Cancer Research Studies
article

First case report of perioperative immunochemotherapy with envafolimab in pulmonary large-cell neuroendocrine carcinoma

Huidong Long, Yunen Lin, Jin-Yu Zhou
article en

Abstract

Pulmonary large-cell neuroendocrine carcinoma (PLCNEC) is a rare and highly aggressive cancer with no standardized perioperative treatment. This study aimed to explore the efficacy and safety of perioperative immunochemotherapy with envafolimab for resectable PLCNEC. We report a 67-year-old male patient with stage IIIA PLCNEC (cT4N0M0) who received four cycles of neoadjuvant immunochemotherapy (envafolimab + carboplatin + etoposide), followed by radical surgery and adjuvant therapy. After neoadjuvant treatment, the tumor shrank by 48.1% and achieved partial response. The patient underwent successful R0 resection and achieved major pathological response. As of May 2025, the patient remained disease-free for 29 months postoperatively, with no grade greater than or equal to 3 adverse events. Notably, clinical benefit was achieved despite negative programmed death-ligand 1 (PD-L1) expression. Perioperative immunochemotherapy with envafolimab is a promising therapeutic option for patients with resectable PLCNEC, even in those with negative PD-L1 expression.

Anti-Cancer Drugs
Guangzhou Medical University Cancer Hospital (CN), Guangzhou Chest Hospital (CN)
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon